Overview

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

Status:
Not yet recruiting

Trial end date:
2022-11-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Ritonavir